AKR1C3, which belongs to the aldo-keto reductase superfamily acting as NADP(H) oxidoreductases, has been considered as the therapeutic target of multiple malignancies and endocrine diseases (21). This evidence concerns the gene AKR1C3 and endocrine system disorder.